Volume overload is an important clinical target in heart failure (HF) management. Diuretics improve symptoms and exercise capacity through reduction in volume overload by increases in urinary volume and sodium excretion in patients with HF, although its effect on mortality is not well confirmed [@bib0005], [@bib0010]. In the acute stage of HF, intravenous diuretics such as furosemide or carperitide are administered at doses sufficient to optimize circulation volume and relieve congestion. However, high doses of loop diuretics are associated with poor prognosis in acute HF, although whether this finding represents cause or effect has not been clarified [@bib0015]. Conventional diuretics sometimes induce not only an excessively rapid reduction in intravascular volume, but also have the potential to reduce glomerular filtration rate, further worsen neuro-humoral activation, and produce electrolyte disturbances. The risk of electrolyte depletion is markedly enhanced when loop diuretics and thiazides are used in combination. Combination diuretic therapy using loop diuretics and thiazides can more than double daily urine sodium excretion to induce weight loss and edema resolution, at the risk of inducing severe hypokalemia in addition to hyponatremia, hypotension, and worsening renal function. Hyponatremia is a significant and independent predictor of outcomes including re-hospitalization and mortality in patients with both acute and chronic HF [@bib0020]. Depletion of potassium and magnesium can predispose patients to serious cardiac arrhythmias.

Recent evidence suggests that vasopressin type 2 receptor antagonists induce an increase in urinary volume without significantly affecting serum potassium, blood pressure, or renal function. Tolvaptan (TLV) is a new type of drug that promotes water diuresis by selectively inhibiting the vasopressin type 2 receptors in collecting tubule [@bib0025], [@bib0030]. In patients hospitalized with volume overload, including HF, who have persistent severe hyponatremia despite water restriction and maximization of conventional diuretics, TLV should be considered in the short term to improve serum sodium concentration in hypervolemic, hyponatremic states [@bib0035]. However, it is not known whether TLV has supplemental effects to enhance the natriuresis that loop diuretics induce. By separately controlling the renal excretion of water and that of electrolytes, TLV may allow optimization of diuretic therapy in HF, and perhaps reduce or minimize the need for loop diuretics.

In this issue of the *Journal of Cardiology Cases*, Nishizaki et al. reported that an 82-old female patient with HF due to severe aortic valve stenosis and cor pulmonale was treated successfully by concomitant administration of TLV with furosemide [@bib0040]. The patient had needed ventilator support because of respiratory deterioration. First, furosemide and spironolactone were administered, and positive end-expiratory pressure was introduced during the night. Then, TLV was chosen because worsening systemic edema and increased pleural effusion, and advancement of cardiomegaly concomitantly with a decrease in potassium. TLV caused an increase in urine volume, a decrease in body weight, and the pleural effusion. The patient gradually recovered to be able to stand with gripping and was discharged from hospital on day 171 after admission. The authors speculated that TLV promoted free-water filtration as its direct effect and sodium filtration as its indirect effect. The mechanism of enhanced diuretic action induced by the concomitant use of TLV with loop diuretics not only promotes water diuresis, known as its primary function, but may also enhance natriuresis induced by loop diuretics. In addition, by optimizing diuretic therapy through a specific effect on water excretion, it might be possible to reduce the dosage of loop diuretics and thereby limit other side effects associated with high doses of loop diuretics such as diminished renal function.

In the clinical setting, volume overload is usually evaluated by systemic signs such as pre-tibial edema, pleural effusion, brain natriuretic peptide, and diameter changes in inferior vena cava on echocardiography. Authors examined plasma (P) and urine (U) osmolality (osm) to know a free-water clearance {free-water clearance = urine volume − (Uosm × urine volume)/(Posm)}. TLV increases free-water clearance as consequences of an increase in urine volume and a decrease in urine osmolality. Thus, this would be the optimal marker to understand whether TLV excretes water alone without increased electrolyte excretion. Repetitive serum Na concentration would be needed to avoid hypernatremia. Udelson et al. [@bib0045] reported that TLV monotherapy without concomitant loop diuretic therapy reduced body weight when compared to placebo without adverse changes in serum electrolytes, during sodium-restricted diet on background medications including angiotensin-converting enzyme inhibitors and beta-blockers. In the current report, the patient did not receive concomitant administration of angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or beta-blocker, because her blood pressure was low and she had severe aortic stenosis. On the other hand, it is reported that TLV has a diuretic effect in patients with severe chronic kidney diseases [@bib0050] and vaptans prevent worsening of renal function compared to conventional therapy [@bib0055]. The key implication of the current case report is that TLV might augment both the diuretic and the natriuretic response to furosemide without adversely affecting hemodynamic variables, neurohormones, renal blood flow, glomerular filtration rate, or electrolytes in patients with HF. It would need further investigations in a larger clinical trial to confirm whether TLV enhances the effects of furosemide.
